1. Generics Bulletin
  2. >>Business
  3. >>Deals

Apotex-Strides tie-up is cleared by ACCC

 
• By Grace Montgomery

Australia’s Competition and Consumer Commission (ACCC) has approved Apotex and Strides Pharma Science’s agreement to merge their Australian businesses, deciding that the transaction “will not substantially lessen competition in any market”.

Australia’s Competition and Consumer Commission (ACCC) has approved Apotex and Strides Pharma Science’s agreement to merge their Australian businesses, deciding that the transaction “will not substantially lessen competition in any market”.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Emcure’s Subsidiary Tillomed Boosts Portfolio With $20m+ Manx Deal

 
• By Adam Zamecnik

The company did not disclose which particular drugs it secured through the deal that further boosted its portfolio that already includes more than 100 assets.

Lupin Boosts UK Presence Through Renascience Acquisition

 
• By Adam Zamecnik

Lupin’s UK subsidiary acquired the British firm for an undisclosed sum of money, adding further assets into the company’s armamentarium.

Viatris Puts Pen To Paper On $335m Opioid Settlement Agreement

 
• By Dean Rudge

Following recent agreements signed by Hikma and Amneal, Viatris has become the latest company to reach a cash settlement resolving allegations that its practices fuelled the US’ deadly opioid epidemic.

Organon Looks To Tap Tocilizumab Potential Following Biogen Acquisition

 
• By Dean Rudge

Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.

More from Business

Despite Multiple Headwinds, Formycon Remains Positive For Its Biosimilars Growth

 
• By Urtė Fultinavičiūtė

Partnering opportunities, paused marketing, approvals, litigations, and many more. Formycon sets out the agenda for 2025, after seeing a bumpy start to the year.

Celltrion Unveils Strategy Amid Series Of Milestones

 
• By Adam Zamecnik

South Korea’s Celltrion has doubled down on its efforts in further building its pipeline, eyeing a target of 22 commercialized products by 2030 while also aiming to submit INDs for 13 novel compounds.

Samsung Rolls Out Second US Soliris Biosimilar – At 30% WAC Discount

 
• By Dean Rudge

Samsung Bioepis and Teva have provided clarity on the pricing of their Epysqli biosimilar to Soliris in the US, as the firms launched only the second rival to the rare diseases treatment.